Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder

Next Previous
Search
Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasedienol (Primary)
  • Indications Anxiety disorders; Social phobia
  • Focus Registrational; Therapeutic Use
  • Acronyms Palisade-1
  • Sponsors VistaGen Therapeutics

    • Most Recent Events

    • 22 Jul 2022 Results presented in a VistaGen Therapeutics Media Release.
    • 22 Jul 2022 According to a VistaGen Therapeutics Media Release, Primary endpoint (Subjective Units of Distress Scale (SUDS)) has not been met.
    • 22 Jun 2022 According to a VistaGen Therapeutics media release, the last patient has completed the study protocol in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top